Author:
Paradise Jordan,Tisdale Alison W.,Hall Ralph F.,Kokkoli Efrosini
Abstract
This article evaluates the oversight of drugs and medical devices by the U.S. Food and Drug Administration (FDA) using an integration of public policy, law, and bioethics approaches and employing multiple assessment criteria, including economic, social, safety, and technological. Throughout, assessments employing both the multiple criteria and a method of expert elicitation are combined with the existing literature, case law, and regulations providing an integrative historical case study approach. The goal is to provide useful information from multiple disciplines and perspectives to guide discussions regarding appropriate oversight frameworks for nanobiotechnology applications under the FDA’s purview.
Publisher
Cambridge University Press (CUP)
Subject
Health Policy,General Medicine,Issues, ethics and legal aspects
Reference134 articles.
1. 70. Id., at 20–21.
2. “FDA Revamps Committee Conflict-of-Interest Rules,”;Finkelstein;Journal of the National Cancer Institute,2006
3. 43. 21 U.S.C. § 360e(c) (2009).
4. 18. The FDA describes a generic drug product as “one that is comparable to an innovator drug product in dosage form, strength, route of administration, quality, performance characteristics and intended use.” See FDA ANDA Process for Generic Drugs, available at (last visited August 20, 2008).
5. Substitution in Regulatory Agencies: FDA Enforcement Alternatives
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献